Search research articles
Contact Us
Filters
Showing results (41-50 of 64) with videos related to
Page
of 7
Sort By:
BMC Cancer
|
February 13, 2016
A phase II study of Epirubicin in oxaliplatin-resistant patients with metastatic colorectal cancer and TOP2A gene amplification
Line S Tarpgaard, Camilla Qvortrup, Sune B Nygård, et al.
Basic & Clinical Pharmacology & Toxicology
|
August 23, 2022
DPYD genotyping and dihydropyrimidine dehydrogenase (DPD) phenotyping in clinical oncology. A clinically focused minireview
Niels Herluf Paulsen, Fie Vojdeman, Stig Ejdrup Andersen, et al.
Acta Oncologica (Stockholm, Sweden)
|
May 3, 2011
Bevacizumab in combination with cetuximab and irinotecan after failure of cetuximab and irinotecan in patients with metastatic colorectal cancer
Finn Ole Larsen, Per Pfeiffer, Dorte Nielsen, et al.
The Lancet. Gastroenterology & Hepatology
|
March 11, 2019
Reduced-dose combination chemotherapy (S-1 plus oxaliplatin) versus full-dose monotherapy (S-1) in older vulnerable patients with metastatic colorectal cancer (NORDIC9): a randomised, open-label phase 2 trial
Stine Braendegaard Winther, Gabor Liposits, Halla Skuladottir, et al.
JCO Precision Oncology
|
March 13, 2025
Multiomics Identifies Potential Molecular Profiles Associated With Outcomes After BRAF-Targeted Therapy in Patients With BRAF V600E-Mutated Advanced Solid Tumors
Martina Eriksen, Anne M Hansen, Annelaura B Nielsen, et al.
Journal of Geriatric Oncology
|
December 9, 2022
Prognostic value of baseline functional status measures and geriatric screening in vulnerable older patients with metastatic colorectal cancer receiving palliative chemotherapy - The randomized NORDIC9-study
Gabor Liposits, Jesper Ryg, Halla Skuladottir, et al.
Acta Oncologica (Stockholm, Sweden)
|
December 19, 2022
Extensive genomic analysis in patients with <i>KRAS</i>-mutated solid tumors shows high frequencies of concurrent alterations and potential targets but has limited clinical impact
Ida Christine Jacobsen, Iben Spanggaard, Martin Højgaard, et al.
Gastric Cancer : Official Journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association
|
May 23, 2026
Circulating tumor DNA-guided response evaluation in patients with previously treated gastroesophageal adenocarcinoma
Cecilie Riis Iden, Nadia Øgaard, Salah Mohammad Mustafa, et al.
Cancers
|
June 2, 2021
Quality of Life in Vulnerable Older Patients with Metastatic Colorectal Cancer Receiving Palliative Chemotherapy-The Randomized NORDIC9-Study
Gabor Liposits, Henrik Rode Eshøj, Sören Möller, et al.
Journal of Clinical Medicine
|
October 14, 2022
The Prognostic Value of Pre-Treatment Circulating Biomarkers of Systemic Inflammation (CRP, dNLR, YKL-40, and IL-6) in Vulnerable Older Patients with Metastatic Colorectal Cancer Receiving Palliative Chemotherapy-The Randomized NORDIC9-Study
Gabor Liposits, Halla Skuladottir, Jesper Ryg, et al.
Page
of 7
Search research articles
Search
Showing results (41-50 of 64) with videos related to
Sort By:
Page
of 7
BMC Cancer
|
February 13, 2016
A phase II study of Epirubicin in oxaliplatin-resistant patients with metastatic colorectal cancer and TOP2A gene amplification
Line S Tarpgaard, Camilla Qvortrup, Sune B Nygård, et al.
Basic & Clinical Pharmacology & Toxicology
|
August 23, 2022
DPYD genotyping and dihydropyrimidine dehydrogenase (DPD) phenotyping in clinical oncology. A clinically focused minireview
Niels Herluf Paulsen, Fie Vojdeman, Stig Ejdrup Andersen, et al.
Acta Oncologica (Stockholm, Sweden)
|
May 3, 2011
Bevacizumab in combination with cetuximab and irinotecan after failure of cetuximab and irinotecan in patients with metastatic colorectal cancer
Finn Ole Larsen, Per Pfeiffer, Dorte Nielsen, et al.
The Lancet. Gastroenterology & Hepatology
|
March 11, 2019
Reduced-dose combination chemotherapy (S-1 plus oxaliplatin) versus full-dose monotherapy (S-1) in older vulnerable patients with metastatic colorectal cancer (NORDIC9): a randomised, open-label phase 2 trial
Stine Braendegaard Winther, Gabor Liposits, Halla Skuladottir, et al.
JCO Precision Oncology
|
March 13, 2025
Multiomics Identifies Potential Molecular Profiles Associated With Outcomes After BRAF-Targeted Therapy in Patients With BRAF V600E-Mutated Advanced Solid Tumors
Martina Eriksen, Anne M Hansen, Annelaura B Nielsen, et al.
Journal of Geriatric Oncology
|
December 9, 2022
Prognostic value of baseline functional status measures and geriatric screening in vulnerable older patients with metastatic colorectal cancer receiving palliative chemotherapy - The randomized NORDIC9-study
Gabor Liposits, Jesper Ryg, Halla Skuladottir, et al.
Acta Oncologica (Stockholm, Sweden)
|
December 19, 2022
Extensive genomic analysis in patients with <i>KRAS</i>-mutated solid tumors shows high frequencies of concurrent alterations and potential targets but has limited clinical impact
Ida Christine Jacobsen, Iben Spanggaard, Martin Højgaard, et al.
Gastric Cancer : Official Journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association
|
May 23, 2026
Circulating tumor DNA-guided response evaluation in patients with previously treated gastroesophageal adenocarcinoma
Cecilie Riis Iden, Nadia Øgaard, Salah Mohammad Mustafa, et al.
Cancers
|
June 2, 2021
Quality of Life in Vulnerable Older Patients with Metastatic Colorectal Cancer Receiving Palliative Chemotherapy-The Randomized NORDIC9-Study
Gabor Liposits, Henrik Rode Eshøj, Sören Möller, et al.
Journal of Clinical Medicine
|
October 14, 2022
The Prognostic Value of Pre-Treatment Circulating Biomarkers of Systemic Inflammation (CRP, dNLR, YKL-40, and IL-6) in Vulnerable Older Patients with Metastatic Colorectal Cancer Receiving Palliative Chemotherapy-The Randomized NORDIC9-Study
Gabor Liposits, Halla Skuladottir, Jesper Ryg, et al.
Page
of 7